Dual inhibition of IL-1α/β [11], IL-1β/IL-17 [12], TNF-α/IL-17 [13, 14], TNF-α/IL-6R [15] or TNF-α/Angiopoietin2 [16] is more potent than single targeting for the treatment of RA and other inflammatory disorders. This evidence concerns the gene IL1B and rheumatoid arthritis.